SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.38-9.0%Nov 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9761)12/15/2003 1:44:52 PM
From: Ian@SI  Read Replies (2) of 52153
 
But it's not clear just how much impact this news will have given the drug is already approved.

Isn't that a little harsh? Surely cutting a year off of a Phase III trial will lower MLNM's costs somewhat even though it appears that treatment will continue for those who want it in both arms of the APEX trial. Can't we also conclude that the early APEX results overwhelmingly favoured Velcade?

The key for Velcade at this point is showing efficacy in other solid tumors

At ASH, I believe MLNM said that first solid tumour results should be released to the public at ASCO. So it would seem that we will have almost another 7 months of waiting ...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News